The aim of these trials, which began in 2020, is to prove the efficacy of this innovative drug in treating ocular inflammation and pain after cataract surgery. For the first time in the world, this new product will use nanoparticles applied to the eye in order to help the drug’s absorption and application. With an […]
About Carme Lopez
This author has yet to write their bio.Meanwhile lets just say that we are proud Carme Lopez contributed a whooping 37 entries.
Entries by Carme Lopez
Mr. Raúl Blanco, Secretary General for Industry and Small and Medium Enterprises, visited Pharmaloop’s new sterile liquids plant, located in Alcalá de Henares (Madrid). Pharmaloop is the first fully autonomous pharmaceutical production center in Spain, with a natural gas cogeneration system that creates its own energy. The visit served to reinforce the company’s commitment to […]
The Minister of Industry, Reyes Maroto, visited Salvat’s new facility today, accompanied by the Mayor of Alcalá de Henares, Javier Rodriguez Palacios and Salvat CEO, Alberto Bueno The new 8,500 m² plant is equipped with the most advanced technology, highest quality standards and the capacity to produce more than 350 million units of sterile formulations […]
Salvat has an agreement with Lee’s Pharmaceuticals to distribute Cetraxal® Plus in China Cetraxal® Plus is the only pharmaceutical product in the world that is available in single-dose vials for external otitis and otitis media. It was launched in 2002 in Spain and is already exported to more than 50 countries The Phase III clinical […]
The new product from Laboratorios Salvat has been recognised as this year’s most innovative Food Supplement for the Immune System Herpix® is a food supplement formulated from natural extracts which helps slow the replication of the Herpes Simplex Virus (HSV), acting from the inside right from the appearance of the first symptom Herpix®, the new […]
Salvat’s new BONECURE project is an innovative medical advancement based on pre-differentiated mesenchymal cells designed to treat patients with bone consolidation problems post-fracture (atrophic pseudoarthrosis). A Phase II clinical trial is being completed with promising results in terms of both efficacy and safety, in patients with long bone pseudoarthrosis. Salvat has conducted this project in […]
A new automated robotic line costing more than €6 million has enabled Cristalmina to increase production from 2.5 million to 15 million units per year By 2021, the company plans to have authorisation to market Cristalmina in more than 26 European countries, which will be followed by Asia and the USA in the years to […]
Again this year, Laboratorios Salvat, S.A. has been granted with the rating “VERY GOOD” by the PROFARMA 2019 program of the Spanish Ministry of Industry, which values pharmaceutical companies based on their excellence in Industrial, economic and Research, Development and Innovation activities. This qualification represents an important recognition of Salvat’s continued efforts towards its objective […]
The research, currently underway both in the United States of America and Europe, will involve an investment of more than $10 million. The worldwide launch of the new medicament to treat this type of external otitis, expected for the end of 2021, reinforces Salvat’s positioning in otology at an international level. The company’s international business […]
Japanese companies from the pharmaceutical sector visit Pharmaloop’s facilities (a Salvat company) through @ICEX and @IcexJapon.